Nano‐Confined Radical Anion as An NIR‐II Photothermal Immunogenic Amplifier for In Situ Cancer Vaccination
Source abstract
Abstract
ABSTRACT Immunogenic cell death (ICD) induced by photothermal therapy holds promise for eliciting systemic antitumor immunity; however, its efficacy is frequently limited by tumor‐intrinsic immunosuppressive defenses. Herein, we report a nano‐confined radical anion as a photothermal immunogenic amplifier that exploits kinetic stabilization to couple high NIR‐II photothermal efficiency with active glutathione depletion for robust in situ cancer vaccination. This amplifier is constructed through the simple co‐assembly of terrylene diimide (TDI) with Pluronic F127, forming nanoparticles in which stable TDI radical anions are generated and kinetically stabilized. The radical anion nanoparticles are further integrated into an injectable hydrogel to create a multifunctional in situ vaccine. This platform ensures prolonged tumor retention, captures tumor‐associated antigens released during ICD, and provides intrinsic adjuvanticity. In murine models, local laser activation of the platform ablates primary tumors and elicits systemic antitumor immune responses associated with suppression of distant tumor growth. The stabilization of organic radical anions by molecular and supramolecular design combines local photothermal therapy with systemic anti‐tumor immunity.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Cancer Immunotherapy and Biomarkers
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Chemical Resource Engineering Beijing University of Chemical Technology Beijing China
CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience National Center for Nanoscience and Technology of China Beijing China
Max Planck Institute for Polymer Research Mainz Germany
Funding
National Natural Science Foundation of China · National Key Research and Development Program of China
References (43)
Show source-provided references
1. 10.1002/advs.20251247010.1002/advs.202512470 ↗
2. 10.1002/advs.20250329910.1002/advs.202503299 ↗
3. 10.1002/advs.20251748010.1002/advs.202517480 ↗
4. 10.1002/advs.202515097J10.1002/advs.202515097J ↗
5. 10.1002/anie.20242483010.1002/anie.202424830 ↗
6. 10.1038/s41467‐025‐57533‐y10.1038/s41467‐025‐57533‐y ↗
7. GSH Depletion Liposome Adjuvant for Augmenting the Photothermal Immunotherapy of Breast Cancer10.1126/sciadv.abc4373 ↗
8. Endogenous/Exogenous Dual‐responsive Nanozyme for Photothermally Enhanced Ferroptosis‐immune Reciprocal Synergistic Tumor Therapy10.1126/sciadv.adq3870 ↗
9. 10.1002/adma.20220170610.1002/adma.202201706 ↗
10. 10.1021/acs.accounts.9b0022110.1021/acs.accounts.9b00221 ↗
11. 10.1007/s11426‐024‐2231‐110.1007/s11426‐024‐2231‐1 ↗
12. 10.1016/j.apsb.2024.09.01710.1016/j.apsb.2024.09.017 ↗
13. 10.1021/jacs.1c1306710.1021/jacs.1c13067 ↗
14. 10.1038/s41467‐019‐08434‐410.1038/s41467‐019‐08434‐4 ↗
15. 10.1002/anie.20090253210.1002/anie.200902532 ↗
16. 10.1039/D2SC06162G10.1039/D2SC06162G ↗
17. 10.1002/smll.20230020310.1002/smll.202300203 ↗
18. 10.1038/s41571‐024‐00892‐010.1038/s41571‐024‐00892‐0 ↗
19. 10.1038/s41565‐024‐01618‐010.1038/s41565‐024‐01618‐0 ↗
20. 10.1016/j.chempr.2025.10275610.1016/j.chempr.2025.102756 ↗
21. 10.1002/anie.20250506910.1002/anie.202505069 ↗
22. 10.1039/D1MH01019K10.1039/D1MH01019K ↗
23. 10.1002/anie.20231853010.1002/anie.202318530 ↗
24. 10.1002/anie.20220483010.1002/anie.202204830 ↗
25. 10.1039/D0CS00718H10.1039/D0CS00718H ↗
26. 10.1038/nri342310.1038/nri3423 ↗
27. 10.1002/anie.20240439510.1002/anie.202404395 ↗
28. 10.1002/agt2.74310.1002/agt2.743 ↗
29. 10.1002/adfm.20241767810.1002/adfm.202417678 ↗
30. 10.1002/adfm.20221064410.1002/adfm.202210644 ↗
31. 10.1002/adfm.20240180610.1002/adfm.202401806 ↗
32. 10.1039/D4CS00679H10.1039/D4CS00679H ↗
33. 10.1038/s41467‐025‐56137‐w10.1038/s41467‐025‐56137‐w ↗
34. 10.1038/s41586‐021‐04243‐210.1038/s41586‐021‐04243‐2 ↗
35. 10.1002/adma.20220815710.1002/adma.202208157 ↗
36. 10.1038/s41578‐023‐00561‐110.1038/s41578‐023‐00561‐1 ↗
37. 10.1038/s41467‐023‐36920‐310.1038/s41467‐023‐36920‐3 ↗
38. 10.1002/anie.20241283910.1002/anie.202412839 ↗
39. 10.1021/jacs.5c0025510.1021/jacs.5c00255 ↗
40. 10.1016/j.ccell.2024.09.01010.1016/j.ccell.2024.09.010 ↗
41. 10.1038/s41563‐022‐01251‐z10.1038/s41563‐022‐01251‐z ↗
42. 10.1038/s41565‐023‐01580‐310.1038/s41565‐023‐01580‐3 ↗
43. 10.1002/advs.20241639010.1002/advs.202416390 ↗